RNC Capital Management LLC grew its position in Johnson & Johnson (NYSE:JNJ) by 2.4% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 236,013 shares of the company’s stock after buying an additional 5,628 shares during the period. Johnson & Johnson accounts for about 2.4% of RNC Capital Management LLC’s portfolio, making the stock its 19th largest position. RNC Capital Management LLC’s holdings in Johnson & Johnson were worth $31,222,000 at the end of the most recent reporting period.
Several other large investors have also recently added to or reduced their stakes in JNJ. Harding Loevner LP purchased a new position in shares of Johnson & Johnson in the 2nd quarter valued at approximately $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. raised its position in shares of Johnson & Johnson by 29.9% in the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock valued at $115,000 after purchasing an additional 200 shares during the last quarter. Lenox Wealth Advisors Inc. raised its position in shares of Johnson & Johnson by 0.6% in the 2nd quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after purchasing an additional 5 shares during the last quarter. IHT Wealth Management LLC raised its position in shares of Johnson & Johnson by 46.4% in the 2nd quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock valued at $122,000 after purchasing an additional 3,467 shares during the last quarter. Finally, Mountain Capital Investment Advisors Inc purchased a new position in shares of Johnson & Johnson in the 2nd quarter valued at approximately $124,000. Institutional investors and hedge funds own 65.89% of the company’s stock.
Several equities analysts recently commented on JNJ shares. Cowen set a $147.00 price objective on shares of Johnson & Johnson and gave the company a “buy” rating in a research report on Thursday, August 24th. BMO Capital Markets reaffirmed a “buy” rating and issued a $145.00 price objective on shares of Johnson & Johnson in a research report on Friday, September 1st. UBS reissued a “buy” rating and set a $148.00 price target on shares of Johnson & Johnson in a research report on Thursday, August 31st. Jefferies Group raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and raised their price target for the stock from $145.00 to $157.00 in a research report on Wednesday, October 11th. Finally, Citigroup raised their price target on shares of Johnson & Johnson from $140.00 to $149.00 and gave the stock a “buy” rating in a research report on Monday, October 23rd. Four investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $145.04.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, topping analysts’ consensus estimates of $1.80 by $0.10. The business had revenue of $19.65 billion for the quarter, compared to analysts’ expectations of $19.29 billion. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The business’s revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the company earned $1.68 EPS. equities analysts predict that Johnson & Johnson will post 7.28 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th were paid a dividend of $0.84 per share. The ex-dividend date was Monday, November 27th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.36%. Johnson & Johnson’s payout ratio is 58.33%.
TRADEMARK VIOLATION NOTICE: “Johnson & Johnson (JNJ) Stake Increased by RNC Capital Management LLC” was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at https://www.com-unik.info/2017/12/16/johnson-johnson-jnj-stake-increased-by-rnc-capital-management-llc.html.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
What are top analysts saying about Johnson & Johnson? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Johnson & Johnson and related companies.